Brazil hopes to be officially free of bird flu in 28 days
SAO PAULO (Reuters) -Brazil began a 28-day bird flu observation period on Thursday which it hopes will show the country's chicken farms are free of the disease after local authorities said a farm where its first outbreak was detected had been fully disinfected.
The outbreak in the world's largest chicken exporter, detected in the town of Montenegro in the state of Rio Grande do Sul, triggered trade bans from multiple countries.
The report from state authorities late on Wednesday that the farm was cleared means that if no other cases of bird flu are detected on Brazilian commercial chicken farms over the next 28 days, the country may be considered free of the disease.
The count starts on Thursday, authorities said.
"We need to ensure that the 28 days of observation occur without new outbreaks," Agriculture Minister Carlos Favaro said after a meeting with Rio Grande do Sul Governor Eduardo Leite this week. "We are reinforcing actions to ensure that everything is perfectly safe," he said.
Eleven active investigations into potential bird flu cases in Brazil are ongoing, including two on commercial chicken farms in Santa Catarina and Tocantins states.
On Wednesday, Tocantins state authorities ruled out an outbreak of bird flu in the farm where the investigation was being conducted, citing preliminary test results. However, the federal government is conducting additional tests, according to the agriculture ministry's website.
WagnerYanaguizawa, an analyst at Rabobank, said the next few days will be decisive in determining whether the outbreak has been contained.
"After 28 days, if there are no new cases from then on, Brazil can declare itself free of the disease," he said, adding that it will then be up to the importers to lift existing trade bans.
"But then trade flows will most likely return to normal," Yanaguizawa said.
(Reporting by Ana Mano and Roberto Samora; editing by Philippa Fletcher)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
4 days ago
- The Star
Global crises disrupt effort to get millions to quit smoking, report says
FILE PHOTO: A man holds a cigarette in his hands in London, Britain April 11, 2023. REUTERS/Maja Smiejkowska/File Photo (Refiles to adjust headline, no changes to text) LONDON (Reuters) -The COVID-19 pandemic, climate change and wars have combined to hamper global governments' plans to reduce tobacco use, derailing efforts to get an estimated 95 million people to stop smoking, a report endorsed by 57 campaign groups said on Friday. Governments had planned to reduce smoking rates among people over 15 by 30% between 2010 and 2025 as part of an action plan tied to global sustainable development targets agreed in 2015. But the timeline to achieve the goal was extended an extra five years in 2024 as other priorities pushed countries to divert resources away from implementing a World Health Organization treaty on tobacco control signed by 168 countries. "This ... delay represents an estimated 95 million additional tobacco users, who would otherwise have quit by 2025," said the report, submitted to the U.N. Economic and Social Council, which oversees global sustainable development. While governments have succeeded in reducing the number of smokers, the failure to hit the 30% reduction target means that 1,207,800,000 people are still smoking globally, instead of the target of 1,112,400,000, based on a Reuters calculation using smoking rates and population figures provided in the report. Published by Action on Smoking and Health Canada and endorsed by the Campaign for Tobacco Free Kids, Cancer Research UK and others, the report warned the delays could result in millions of additional deaths from tobacco use if sustained. The U.N. has already acknowledged that funding shortfalls, geopolitical tensions and pandemic-linked disruptions have pushed the world off track on most of the 17 wide-ranging sustainable development goals. Those goals aim, among other things, to reduce poverty and hunger and increase access to healthcare and education. The groups that endorsed ASH Canada's report urged governments to redouble their efforts on tobacco control policies such as tax increases and smoking bans. (Reporting by Emma Rumney; Editing by Joe Bavier)
The Star
4 days ago
- The Star
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Administration's pullback in aid spending. Some AIDS experts, including activists and doctors, say the Gilead drug, lenacapavir, could help end the 44-year-old epidemic that infects 1.3 million people a year and is estimated by the World Health Organization to have killed more than 42 million. An FDA approval decision is expected by June 19 for lenacapavir, which proved to be nearly 100% effective at preventing HIV in large trials. If the Food and Drug Administration green lights the drug, and its view is seconded by the WHO, the shots could start to roll out early in 2026 to at least 2 million people in 18 low-income countries based on Gilead's agreement with the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund, a worldwide partnership targeting HIV, tuberculosis and malaria. Gilead agreed to provide lenacapavir at cost for two-to-three years while six generic drugmakers, which were granted licenses to make the medicine for low-income countries, ramp up production. Experts said a successful launch of a long-acting HIV prevention drug could help stall the epidemic. Until recently, the only pre-exposure prophylaxis (PrEP) options for people at high risk of infection were daily pills, requiring careful adherence to be effective. "You can foresee a day where there are no new HIV diagnoses. It doesn't happen if we only do this in the U.S.," Gilead Chief Commercial Officer Johanna Mercier said. "We need to make sure we have a global approach to this launch." PEPFAR being part of the effort is Gilead's intent and goal, Mercier said. "Unfortunately, if they're not part of that mix, our goal is still to meet that objective of 2 million people getting access." Wall Street has a close eye on lenacapavir, one of the highest-profile drugs to undergo FDA review since President Donald Trump named Robert F. Kennedy Jr. as health secretary and promised to upend the status quo. Most of the drug's profits are expected in the U.S., with annual sales reaching $1 billion by next year, according to analysts' estimates compiled by LSEG. 'INCREDIBLE DISMAY' Whether all of the agreed funding for low-income countries - most of which are in Africa - will come through is unclear. Countries that rely on aid are already reeling from funding cuts by the Trump Administration, including to PEPFAR, and AIDS researchers are bracing for the worst. The United Nations program on HIV/AIDS earlier this month said many HIV prevention programs supported by PEPFAR were stalled, although services for pregnant and breastfeeding women were technically exempt from the cuts. Peter Sands, executive director of the Global Fund, told Reuters the group intends to fund as much of the lenacapavir rollout as possible, but it will need to start slowly. "It's not just the uncertainty over PEPFAR's funding that's an issue, but the uncertainty over our funding," Sands said, adding that the group's first priority is treating people already infected with the deadly virus. Much will depend on the success of the Global Fund's effort to raise $18 billion to fund its work from 2027-2029. The U.S. is its largest donor, committing $6 billion in the previous funding round. It is unclear what the U.S. may provide this round, or whether other big governments will step up. UNAIDS estimates that the permanent discontinuation of HIV prevention and treatment programs supported by PEPFAR would lead to an additional 6.6 million new HIV infections between 2025 and 2029. The U.S. State Department, which oversees PEPFAR, did not respond to a request for comment. Gilead declined to comment on its manufacturing cost for lenacapavir, whose U.S. price is likely to be on par with current preventive medications at around $25,000 per year. ViiV Healthcare's Apretude, an injection given every two months, costs about 124.20 pounds ($168) in low- and middle-income countries. Mitchell Warren, executive director of the AIDS nonprofit AVAC, estimates the eventual annual cost at $100-$120. The lower the price, the more people who could receive it, he said. Warren said PEPFAR could still participate, and others may come forward. The Gates Foundation and the Children's Investment Fund Foundation are "actively involved in all of these conversations," he said, as is the Elton John AIDS Foundation. Linda-Gail Bekker of the University of Cape Town, who led lenacapavir clinical trials in South Africa and Uganda, said she was elated when she first saw the findings. "The huge feeling I have now is one of incredible dismay," said Bekker of uncertainty over the Trump administration's commitment to PEPFAR and HIV prevention in poor nations. "It felt like the stars were aligning, and one of the stars has fallen out of the sky." (Reporting by Julie Steenhuysen in Chicago and Deena Beasley in Los Angeles; additional reporting by Jennifer Rigby in London; editing by Caroline Humer and Bill Berkrot)
The Star
5 days ago
- The Star
Brazil declared free of foot-and-mouth disease without vaccination, says Abrafrigo
FILE PHOTO: A herd of cattle is seen in the city of Tailandia in the state of Para, Brazil March 17, 2020. Reuters/Pilar Olivares/File Photo SAO PAULO (Reuters) - The World Organisation for Animal Health (WOAH) has recognized Brazil as a country free of foot-and-mouth disease without vaccination, Brazilian beef lobby Abrafrigo said in a statement on Thursday. Brazil is the world's top beef exporter and the certificate could contribute to opening new markets. This is the first time that the country has achieved this level of excellence in its sanitary controls, according to Abrafrigo. The lobby, which represents some of the largest Brazilian meatpackers such as Marfrig, said the recognition was a "historic moment for the beef agro-industrial chain." "The new status also brings new challenges and responsibilities for all actors involved, with the aim of maintaining the herd in adequate sanitary conditions and increasingly strengthening the country's role as a major producer and supplier of animal-origin food for Brazil and the world," it added. The Brazilian Agriculture Ministry did not immediately respond to a request for comment. (Reporting by Ana Mano; Writing by Isabel Teles; Editing by Bernadette Baum and Tomasz Janowski)
